Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The objective is to monitor and quality assure the efficacy, including effects on quality of
life, and safety of Monofer® in Chronic Kidney Disease and Inflammatory Bowel Disease patient
populations when Monofer® is used according to the Monofer® label (Summary of Product
Characteristics, SPC) in current clinical practice and where standard routines are being
followed.